Abeona Therapeutics Inc
Uždarymo kaina
5.62 -1.92
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
5.61
Max
5.83
Pajamos | 3.4M -17M |
|---|---|
Pardavimai | 3.3M 8.7M |
P/E Sektoriaus vid. | 5.894 50.958 |
Pelno marža | -195.814 |
Darbuotojai | 226 |
Rekomendacijos | Stiprus pirkimas |
|---|---|
12 mėnesių prognozė | +245.28% upside |
Kitas uždarbis | 2026-08-13 |
|---|
Rinkos kapitalizacija | -4.4M 279M |
|---|---|
Ankstesnė atidarymo kaina | 7.54 |
Ankstesnė uždarymo kaina | 5.62 |
Abeona Therapeutics Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
